Sinequan

Insomnia, Neurotic depression, Depression + 8 more

Treatment

20 Active Studies for Sinequan

What is Sinequan

Doxepin

The Generic name of this drug

Treatment Summary

Doxepin is a drug prescribed to treat depression, anxiety, and insomnia. It is a type of medication known as a tertiary amine that helps to balance the levels of certain chemicals in the brain. Doxepin was first approved by the FDA in 1969 for the treatment of depression and later approved for the treatment of insomnia in 2010. It belongs to the same drug family as amitriptyline, clomipramine, desipramine, imipramine, nortriptyline, protriptyline, and trimipramine.

Sinequan

is the brand name

image of different drug pills on a surface

Sinequan Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Sinequan

Doxepin

1969

307

Effectiveness

How Sinequan Affects Patients

Doxepin is a type of antidepressant that works by decreasing the activity of the brain. It can also help with insomnia and anxiety. It may take two weeks for the antidepressant effects to show, but the sedative effects are immediate. At high doses, it can cause central nervous system depression and its anticholinergic and antiadrenergic effects can limit its efficacy.

How Sinequan works in the body

Doxepin works by blocking histamine receptors in the skin to reduce inflammation. It also works on the central nervous system to increase levels of serotonin and norepinephrine. This helps improve mood and reduce depression symptoms. Doxepin may also desensitize serotonin 1A receptors and beta-adrenergic receptors. It is believed to increase dopamine transmission in the frontal cortex which is thought to help improve mood.

When to interrupt dosage

The advocated dose of Sinequan is contingent upon the determined condition, for example Depression, Involutional, Mental Disorder, Organic and Insomnia. The dose can be found in the table below, based on the technique of delivery (e.g. Oral or Tablet - Oral).

Condition

Dosage

Administration

Insomnia

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Neurotic depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Generalized Anxiety Disorder

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Neuropathic Pain

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Itching

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Behcet Syndrome

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Alcoholism

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Neurodermatitis

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Warnings

Sinequan has four contraindications and thus should not be taken when encountering any of the conditions shown in the following table.

Sinequan Contraindications

Condition

Risk Level

Notes

untreated narrow angle glaucoma

Do Not Combine

Pulse Frequency

Do Not Combine

Urinary Retention

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Doxepin may interact with Pulse Frequency

There are 20 known major drug interactions with Sinequan.

Common Sinequan Drug Interactions

Drug Name

Risk Level

Description

4-Methoxyamphetamine

Major

Doxepin may increase the vasopressor activities of 4-Methoxyamphetamine.

Acepromazine

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Doxepin is combined with Aclidinium.

Alfuzosin

Major

Doxepin may increase the hypotensive activities of Alfuzosin.

Aripiprazole

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Sinequan Toxicity & Overdose Risk

Doxepin is toxic in high doses, with a lethal dose of 180mg/kg in mice and 147mg/kg in rats. Overdosing on doxepin can cause seizures, heart rhythm problems, loss of consciousness, low blood pressure, central nervous system depression, changes on an EKG, and even death. In fertility studies, doxepin was found to reduce the time of copulation, decrease the number of viable embryos, decrease litter size, and decrease sperm motility. There is no evidence that doxepin causes cancer or mutations.

image of a doctor in a lab doing drug, clinical research

Sinequan Novel Uses: Which Conditions Have a Clinical Trial Featuring Sinequan?

1020 active trials are being conducted to assess the potential of Sinequan in managing Generalized Anxiety Disorder, Atopic Dermatitis and Bipolar Disorder.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

174 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

Depressive Disorder, Major

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Depression

290 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Neurotic depression

0 Actively Recruiting

Depressive Disorder, Major

0 Actively Recruiting

Itching

3 Actively Recruiting

Phase 3, Not Applicable

Behcet Syndrome

1 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Neurodermatitis

0 Actively Recruiting

Sinequan Reviews: What are patients saying about Sinequan?

5

Patient Review

8/30/2010

Sinequan for Itching

This medication has been a lifesaver for me on two different occasions when I've suffered from chronic urticaria. It's completely alleviated my problem when taken with other OTC antihistamines. I only need to take 10 mg each night for 3-4 weeks during flare-ups now. The main side effects I've experienced are dry mouth and an extreme drop in libido due to decreased lubrication.

5

Patient Review

1/17/2018

Sinequan for Nerve Pain

My neurologist prescribed this for me 15 years ago when I was 50 and suffering from peripheral neuropathy pain. It's been a godsend, allowing me to walk without pain.

4.7

Patient Review

7/29/2016

Sinequan for Anxiousness associated with Depression

Doxepin has been a game-changer for me. It's helped with my anxiety, depression, and insomnia. I have experienced dry mouth as a side effect; however, it hasn't been bad enough to make me want to stop taking the medication.

4.3

Patient Review

5/1/2010

Sinequan for Anxiousness associated with Depression

Sinequan has been an utter game-changer for me. I was struggling with anxiety and depression to the point where I rarely left my house, but this medication helped me get my life back. The only downside is that I've gained about 30 pounds since starting it.

3.7

Patient Review

10/8/2011

Sinequan for Anxious

This medication didn't do much for my constipation.

3

Patient Review

11/2/2011

Sinequan for Depression

I started taking this treatment two weeks ago. So far, I haven't seen a huge difference, but it takes time for medications to build up in your system so I'm hopeful.

2.3

Patient Review

9/24/2013

Sinequan for Depression

I'm still struggling with depression, and this medication hasn't been helping.

1.7

Patient Review

3/16/2014

Sinequan for Depression

This didn't help me at all and I had a lot of trouble sleeping.

1

Patient Review

3/26/2010

Sinequan for Bipolar Depression

The side effects of this medication were really terrible. I gained a lot of weight, felt groggy and irritable the next day, and would wake up in the middle of the night and eat everything in sight. I stopped taking it after only 8 months because it was making me so unhealthy.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sinequan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much sinequan can you take for sleep?

"Adults should take 6 milligrams (mg) of the medication once a day. Older adults should take 3 mg of the medication once a day. The doctor may adjust the dose as needed."

Answered by AI

Is sinequan still prescribed?

"The brand name Sinequan is no longer available in the United States. However, generic forms are still available."

Answered by AI

What is the drug sinequan used for?

"This medication is used to improve mood, relieve tension and anxiety, help with sleep, and increase energy. It belongs to a class of medications called tricyclic antidepressants."

Answered by AI

Is doxepin a good sleeping pill?

"This results in improvement in depression or anxiety.

Doxepin is used to treat anxiety or depression and also to treating insomnia by increasing levels of certain chemicals in the brain, which improves depression or anxiety."

Answered by AI

Clinical Trials for Sinequan

Have you considered Sinequan clinical trials?

We made a collection of clinical trials featuring Sinequan, we think they might fit your search criteria.
Go to Trials
Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Have you considered Sinequan clinical trials?

We made a collection of clinical trials featuring Sinequan, we think they might fit your search criteria.
Go to Trials
Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Fort Bend ISD in Sugar Land, United States.

Wellbeing Interventions for Anxiety

10 - 20
All Sexes
Sugar Land, TX

The goal of this clinical trial is to learn if psychology and music based interventions can impact anxiety and overall wellbeing in adolescents enrolled in choral music classes. The main questions it aims to answer are: Do specific psychology and music based breathing interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based performance anxiety reduction interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based emotion regulation interventions impact anxiety and overall wellbeing in adolescents? Researchers will compare results of pre-test data, post-test data, qualitative interviews, and surveys of adult choral directors to see if there is a measurable impact on adolescent anxiety and overall wellbeing. Participants will: * Use box breathing during choral music warm-ups to connect choral breathing to breathing for anxiety reduction * Use "magnify" technique to compare cognitive distortions regarding an upcoming performance that may cause anxiety to the most likely realistic outcome * Use emotion regulation through song lyrics technique to connect lyrics of choral music repertoire to participants experienced emotions

Waitlist Available
Has No Placebo

Fort Bend ISD

Jane Kuehne, PhD

Have you considered Sinequan clinical trials?

We made a collection of clinical trials featuring Sinequan, we think they might fit your search criteria.
Go to Trials